A once-daily targeted tablet is reshaping expectations in one of oncology’s toughest diseases. New phase 3 data show the Daraxonrasib Pancreatic Cancer Pill nearly doubled median survival for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), compared with standard chemotherapy. Clinicians typically identify pancreatic cancer late. Outcomes in metastatic disease have barely shifted for decades, especially after first-line chemotherapy.…